[http://img2.ymlp282.net/TEIC_header.jpg]
The ESWI News Bulletin offers you a selection of influenza-related articles collected from a range of media sources. It does not represent the opinions of ESWI or its members.
Kindly e-mail any comments or questions regarding the ESWI News Bulletin to info@eswi.org<mailto:info@eswi.org>.
Tamiflu is effective against influenza, major study finds
New analysis of efficacy data confirms that timely administration of the antiviral influenza drug Tamiflu considerably reduces the impact of an influenza infection in adults. The study results have now been published in The Lancet.
Read the Lancet article<http://email.ettbioclosingconference.eu/usbsalauqqwwapauhbafawsue/click.php>
Read the press statement<http://email.ettbioclosingconference.eu/usbuaiauqqwwacauhbaiawsue/click.php>
'People with diabetes benefit from flu vaccination'
Anne Felton, President of the Foundation of European Nurses in Diabetes (FEND) says people with diabetes can benefit from vaccination against flu and other infectious diseases.
Read more<http://email.ettbioclosingconference.eu/usbearauqqwwavauhbaaawsue/click.php>
Council of the European Union conclusions on vaccination
On 1 December 2014, the Council of the European Union adopted conclusions on vaccinations as an effective tool in public health. The Conclusions recognize that an evidence-based, cost-effective, safe and efficient immunization system is an integral part of a well-functioning health system.
Read more<http://email.ettbioclosingconference.eu/usbmatauqqwwavauhbagawsue/click.php>
Eurosurveillance Rapid Communication
Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype
Read the full communication<http://email.ettbioclosingconference.eu/usbjakauqqwwaoauhbazawsue/click.php>
[http://img2.ymlp282.net/TEIC_Eswifooter.png]
eswi.org<http://email.ettbioclosingconference.eu/usbbaaauqqwwavauhbafawsue/click.php>
flucommunity.org<http://email.ettbioclosingconference.eu/usbhaiauqqwwapauhbalawsue/click.php>
flucentre.net<http://email.ettbioclosingconference.eu/usbwaiauqqwwadauhbanawsue/click.php>
Join us on Facebook<http://email.ettbioclosingconference.eu/usbqagauqqwwavauhbazawsue/click.php>
Follow us on Twitter<http://email.ettbioclosingconference.eu/usbyaaauqqwwaxauhbarawsue/click.php>
If you cannot read this email properly, please click here<http://email.ettbioclosingconference.eu/ushsadauqqwwapauhbapawsue/click.php>
________________________________
Unsubscribe / Change Profile<http://email.ettbioclosingconference.eu/uguhyqyjgsgwsuegusybggujumsj>
Powered door YMLP<http://email.ettbioclosingconference.eu/m/>
hVIVO is the new name of Retroscreen Virology! (from 15 April 2015). hVIVO is a rapidly growing UK life sciences company pioneering a technology platform which uses human challenge models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled, clinical environment. Our belief is that the best way to understand human disease is by studying it in humans, not laboratory models.
No comments:
Post a Comment